JSJaime Soto

Jaime Soto

*This is an algorithmically generated author record based on publicly available information.

Jaime Soto has a total of 171 co-authors. Here are the top co-authors by number of shared publications:

  • Paula Soto

    FUNDERMA (Fundación Nacional de Dermatología), Santa Cruz, Bolivia

    8 shared publications
  • J. Berman

    7 shared publications
  • Jonathan Berman

    Fundación Nacional de Dermatología (FUNDERMA), Santa Cruz, Bolivia; Hospital Dermatológico de Jorochito, Santa Cruz, Bolivia; Hospital Local, Palos Blancos, Bolivia; Centro de Investigaciones Bioclínicas de la Fundación Fader (FADER-CIBIC), Bogota, Colombia; AB Foundation, North Bethesda, Maryland

    7 shared publications
  • Julia Toledo

    Fundación Nacional de Dermatología (FUNDERMA), Santa Cruz, Bolivia; Hospital Dermatológico de Jorochito, Santa Cruz, Bolivia; Hospital Local, Palos Blancos, Bolivia; Centro de Investigaciones Bioclínicas de la Fundación Fader (FADER-CIBIC), Bogota, Colombia; AB Foundation, North Bethesda, Maryland

    7 shared publications
  • J. Toledo

    Consorcio de Investigaciones Bioclinicas, Bogotá , Colombia

    5 shared publications
  • J. Engel

    Zentaris, Frankfurt am Main , Germany

    4 shared publications

Latest Publications

  • Treatment of Bolivian Leishmania braziliensis Cutaneous and Mucosal Leishmaniasis

    by Jaime Soto, Patricia Gutiérrez, Paula Soto, David Paz, Eduardo Cayhuara, Carmen Molina, Mia Sánchez, Jonathan Berman

    Although infection with Leishmania braziliensis is perhaps the key reason to treat New World cutaneous leishmaniasis (CL) and mucosal leishmaniasis (ML), the total literature contains relatively few reported cases. With the aim of supplementing the meager clinical information available, we searched the records of Jorochito (Dermatology) Hospital, Bolivia, for the years 1999–2020 and identified treatment records for 1,696 naive CL patients and 355 naive ML patients. Because follow-up was poor for this real-world treatment experience in the developing world, only 255 CL patients (15%) and 114 ML patients (32%) attended follow-up at Hospital. We therefore engaged in an Active Search for “lost” patients, located a further 542 CL patients (32%) and 142 ML patients (44%), thus eventually accomplished follow up on 697 CL patients (41%) and 256 ML patients (72%). Granular adverse event data derived from hospital records is listed for the 902 CL and 86 ML patients administered Glucantime intramuscularly, the 401 CL and 202 ML patients administered Glucantime intravenously, and the 163 CL and 89 ML patients administered miltefosine orally. Efficacy was obtained from hospital records for patients seen at hospital and from patient recall communicated by telephone for the patients found in the Active Search. The overall CL cure rate was 508 of 697 CL patients (73%) with follow-up: intramuscular Glucantime—196/293 (67%); intravenous Glucantime—90/126 (71%); intralesional Glucantime—34/54 (63%); oral miltefosine—52/69 (75%). The overall ML cure rate was 161 of 256 ML patients (63%) with follow-up: intramuscular Glucantime—26/48 (54%); intravenous Glucantime—66/104 (63%); intravenous amphotericin B deoxycholate—19/35 (54%); oral miltefosine—50/71 (70%). We offer this extensive adverse event and efficacy experience as useful guides for clinicians presented with a L. braziliensis infection. The cure rates also illustrate the quandary of New World CL and ML chemotherapy: sufficiently high to be useful but nevertheless needing augmentation with new agents.


  • Open Access

    Case Report: COVID-19 Misdiagnosed as a Drug Reaction to Miltefosine

    by Jaime A. Soto, María Isabel Méndez, Jonathan D. Berman

    We present case reports of two patients treated with miltefosine for mucocutaneous leishmaniasis whose gastrointestinal symptoms were initially diagnosed as a drug reaction and only later recognized as due to COVID-19. Gastrointestinal symptoms of COVID-19 are unusual, whereas gastrointestinal adverse drug reactions are very common. These reports exemplify that this infrequent presentation of COVID-19 is likely to be ascribed to a more common etiology such as a gastrointestinal drug reaction.


  • Miltefosine Treatment of Cutaneous Leishmaniasis

    by Jaime A Soto, Jonathan D Berman

    Cutaneous leishmaniasis (CL) generally presents as a papule that enlarges to a nodule and, if it ulcerates, does so over 1–3 months. The primary Leishmania species causing cutaneous leishmaniasis are diverse: L. (Viannia [V.]) braziliensis, L. (V.) guyanensis, L. (V.) panamensis, L. (V.) peruviana, L. (Leishmania [L.]) mexicana, L (L.) amazonensis, and L. infantum (chagasi) in the New World; and L. major, L. tropica, L. aethiopica, and L. infantum in the Old World. Mucosal disease may result from dissemination particularly of members of the Leishmania (V.) complex to the...


  • Mass Drug Administration of Triclabendazole for Fasciola Hepatica in Bolivia

    by Sergio Mollinedo, Patricia Gutierrez, Rosa Azurduy, Freddy Valle, Alejandra Salas, Zoraida Mollinedo, Paula Soto, Cleye F. Villarroel, Janet Ransom, Robb Lawrence, et al.

    Human infection with Fasciola hepatica leads to obstruction of the common bile duct by adult worms and disease characterized by biliary colic, epigastric pain, and nausea. Recommended treatment is a single dose of triclabendazole (TCBZ) (10 mg/kg). Because in the 1990s the Bolivian Altiplano bordering Lake Titicaca was thought to have the highest prevalence of human fascioliasis worldwide, the Bolivian Ministry of Health instituted TCBZ mass drug administration (MDA). From 2008 to 2016 (excepting 2015), one dose of 250 mg was administered, usually in September/October, to each resident of highly endemic regions willing to participate. This is apparently the first reported use of MDA for Fasciola. The proportion of persons in key regions receiving TCBZ MDA was 87% in 2016. In 2017, we resurveyed key regions, and found that the MDA program had been dramatically successful. Whereas Fasciola prevalence was reported as 26.9% in Huacullani/Tiahuanaco and 12.6% in Batallas in 1999, there was 0.7% prevalence in Huacullani/Tiahuanaco and 1% in Batallas in 2017. However, lessons from schistosomiasis control efforts suggest that for sustained control of Fasciola infection, Fasciola MDA needs to be maintained and coupled with measures to control infection in the intermediary snail and in the animal hosts of F. hepatica.


  • Miltefosine Combined with Intralesional Pentamidine for Leishmania braziliensis Cutaneous Leishmaniasis in Bolivia

    by Jaime Soto, Paula Soto, Andrea Ajata, Daniela Rivero, Christian Luque, Carlos Tintaya, Jonathan Berman, P. de Rivero

    Bolivian cutaneous leishmaniasis due to Leishmania braziliensis was treated with the combination of miltefosine (150 mg/day for 28 days) plus intralesional pentamidine (120 μg/mm2 lesion area on days 1, 3, and 5). Ninety-two per cent of 50 patients cured. Comparison to historic controls at our site suggests that the efficacy of the two drugs was additive. Adverse effects and cost were also additive. This combination may be attractive when a prime consideration is efficacy (e.g., in rescue therapy), avoidance of parenteral therapy, or the desire to treat locally and also provide systemic protection against parasite dissemination.


  • Open Access

    Harmonized clinical trial methodologies for localized cutaneous leishmaniasis and potential for extensive network with capacities for clinical evaluation

    by Piero Olliaro, Max Grogl, Marina Boni, Edgar M Carvalho, Houda Chebli, Mamoudou Cisse, Ermias Diro, Gláucia Fernandes Cota, Astrid C Erber, Endalamaw Gadisa, et al.

    Progress with the treatment of cutaneous leishmaniasis (CL) has been hampered by inconsistent methodologies used to assess treatment effects. A sizable number of trials conducted over the years has generated only weak evidence backing current treatment recommendations, as shown by systematic reviews on old-world and new-world CL (OWCL and NWCL). Using a previously published guidance paper on CL treatment trial methodology as the reference, consensus was sought on key parameters including core eligibility and outcome measures, among OWCL (7 countries, 10 trial sites) and NWCL (7 countries, 11 trial sites) during two separate meetings. Findings and level of consensus within and between OWCL and NWCL sites are presented and discussed. In addition, CL trial site characteristics and capacities are summarized. The consensus reached allows standardization of future clinical research across OWCL and NWCL sites. We encourage CL researchers to adopt and adapt as required the proposed parameters and outcomes in their future trials and provide feedback on their experience. The expertise afforded between the two sets of clinical sites provides the basis for a powerful consortium with potential for extensive, standardized assessment of interventions for CL and faster approval of candidate treatments. The term ‘cutaneous leishmaniasis’ (CL) includes a range of manifestations affecting the skin caused by Leishmania parasites across several continents. While not life-threatening, CL can be invalidating and disfiguring, or become complicated. Today, there is no satisfactory treatment for CL that is effective and safe. Faced with no investments into developing drugs for CL, clinical researchers have tried many treatments over the years, but little progress has been made. One of the reasons is the lack of standardized methodologies in conducting these trials which makes it difficult to collate and compare results. Clinical researchers now realize that their efforts can be brought to fruition if common methodologies are available and applied. This paper summarizes the principles and parameters agreed upon by researchers of how to identify patients and how to measure treatment effects in a way that will make it possible to gather convincing evidence of whether a treatment works or not. Adhering to these principles will allow faster progress towards offering better care to patients with this neglected disease.


  • Intralesional Pentamidine: A Novel Therapy for Single Lesions of Bolivian Cutaneous Leishmaniasis

    by Jaime Soto, David Paz, Daniela Rivero, Paula Soto, Jorge Quispe, Julia Toledo, Jonathan Berman

    A novel therapy, intralesional (IL) pentamidine, was compared to intralesional therapy with antimony (ILSb), a World Health Organization–recommended therapy, for single Bolivian Leishmania braziliensis lesions. In Study 1, 90 patients were randomized equally between three injections of ILSb over 5 days, five injections of ILSb over 11 days, and three injections of IL pentamidine (120 μg/mm2 lesion area [ILPenta-120-3]) over 5 days. Cure rates at 6 months were 57% for ILSb-3 injections, 73% for ILSb-5 injections, and 72% for ILPenta-120-3 injections. Adverse effects were local irritation and injection-site pain—ILSb (60 patients): mild (25), moderate (4); IL pentamidine (30 patients): mild (4), moderate (3). In Study 2, 60 patients were randomized equally between five injections of ILSb and three injections of a double dose of IL pentamidine (240 μg/mm2 [ILPenta-240-3]). In Study 2, cure rates were 67% for ILSb-5 injections and 73% for ILPenta-240-3. For three IL injections of pentamidine, efficacy was optimized at a dose of 120 μg/mm2 lesion area. The cure rate of that regimen was similar to that for ILSb-5 injections and nonstatistically larger than that of ILSb-3 injections. IL pentamidine is an attractive alternative to ILSb on the basis of efficacy for Bolivian L. braziliensis, the threat of Sb-resistant parasites, tolerance, and patient convenience of three visits over 5 days.


  • In Vivo Antileishmanial Efficacy of Miltefosine AgainstLeishmania(Leishmania)amazonensis

    by María F. García Bustos, Alejandra Barrio, Gabriela G. Prieto, Emma M. de Raspi, Rubén O. Cimino, Rubén M. Cardozo, Luis A. Parada, Matthew Yeo, Jaime Soto, Delfor A. Uncos, et al.

    Leishmaniasis, a disease caused by parasites of the Leishmania genus, constitutes a significant health and social problem in many countries and is increasing worldwide. The conventional treatment, meglumine antimoniate (MA), presents numerous disadvantages, including invasiveness, toxicity, and frequent therapeutic failure, justifying the attempts at finding alternatives to the first-line therapy. We have studied the comparative long-term efficacy of MA against miltefosine (MF) in Leishmania infection in experimental mice. The criteria for efficacy evaluation were footpad lesion size, anti-Leishmania antibodies level, histopathology of the site of inoculation (right footpad, RFP), splenic index (SI), and the presence of parasites in RFP, spleen, and liver, determined by polymerase chain reaction (PCR). Swiss mice, infected with Leishmania (Leishmania) amazonensis were treated, at different time points (5 and 40 days after infection) with either MA or MF. The efficacy of MF was better than that of MA for inhibiting lesions and for reducing tissue damage and presence/load of amastigotes in spleen and liver. Moreover, early administration of MF produced a clear reduction in splenomegaly and was equal in reducing antibody titles in comparison with MA. Our results demonstrated that MF is an effective and safe therapeutic alternative for leishmaniasis by L. (L.) amazonensis and is more efficacious than MA.


  • Open Access

    Reply to Monge-Maillo et al

    by Jaime Soto, Jonathan Berman

    Monge-Maillo et al [1] raise key issues with respect to New World cutaneous leishmaniasis (CL). One issue is, as stated, that the use of local versus systemic therapy has to address the possibility that local therapy could be associated with a higher risk of later mucosal leishmaniasis (ML). We agree that the risk of ML is an important factor in evaluating local therapy, although we quantitate that risk differently.